Marksans Pharma Full Year 2025 Earnings: In Line With Expectations

Simply Wall St

Marksans Pharma (NSE:MARKSANS) Full Year 2025 Results

Key Financial Results

  • Revenue: ₹26.2b (up 21% from FY 2024).
  • Net income: ₹3.81b (up 21% from FY 2024).
  • Profit margin: 14% (in line with FY 2024).
  • EPS: ₹8.40 (up from ₹6.92 in FY 2024).

We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

NSEI:MARKSANS Revenue and Expenses Breakdown July 19th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Marksans Pharma Meets Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) was also in line with analyst expectations.

The primary driver behind last 12 months revenue was the United States and North America segment contributing a total revenue of ₹12.4b (47% of total revenue). Explore how MARKSANS's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 17% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India.

Performance of the Indian Pharmaceuticals industry.

The company's share price is broadly unchanged from a week ago.

Risk Analysis

What about risks? Every company has them, and we've spotted 2 warning signs for Marksans Pharma (of which 1 can't be ignored!) you should know about.

Valuation is complex, but we're here to simplify it.

Discover if Marksans Pharma might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.